(19)
(11) EP 4 824 098 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24841336.1

(22) Date of filing: 12.12.2024
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61K 39/395(2006.01)
A61P 37/06(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2803; A61P 37/06; C07K 2317/33; C07K 2317/75; C07K 2317/92; C07K 2317/34
(86) International application number:
PCT/US2024/059792
(87) International publication number:
WO 2025/128836 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 13.12.2023 US 202363609523 P

(71) Applicant: Eli Lilly and Company
Indianapolis, IN 46285 (US)

(72) Inventors:
  • BALASUBRAMANIAM, Deepa
    Indianapolis, Indiana 46206-6288 (US)
  • LIN, Yaqiong
    Indianapolis, Indiana 46206-6288 (US)
  • MUENCH, David
    Indianapolis, Indiana 46206-6288 (US)
  • NA, Songqing
    Indianapolis, Indiana 46206-6288 (US)
  • WITEK, Marta Antonina
    Indianapolis, Indiana 46206-6288 (US)
  • XU, Jianghuai
    Indianapolis, Indiana 46206-6288 (US)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)

   


(54) LAG-3 AGONIST ANTIBODIES